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Abstract 
Context: Alterations of protein turnover may contribute to the progressive decline of muscle mass with 
ageing.  
 
Objective: The effects of near physiological recombinant growth hormone (GH) and /or testosterone (T) 
administration to older men on whole body protein kinetics (WBPK) and muscle gene expression.  
 
Design, settings, and participants:  A six months randomised, double blind, placebo controlled trial in 
twenty one healthy elderly men aged 65 to 75 years. Participants were randomised to receive placebo 
GH and placebo T (P), GH and placebo T (GH), T and placebo GH (T) or GH and T (GHT). 
 
Interventions:  Leucine rate of appearance (Ra, index of proteolysis), non-oxidative leucine disposal Rd 
(NOLD, an index of protein synthesis) and leucine oxidation rate were measured with an infusion of L- [1-
13C] leucine. Muscle biopsies for the measurement of gene expression, body composition and aerobic 
capacity (VO2max). 
 
Results: Serum IGF-I levels increased significantly with GH and GHT (p<0.001) compared to placebo. T 
increased significantly only in the T group (P=0.028). Leucine Ra and NOLD increased with GH (P=0.015, 
P=0.019) and GHT (P=0.017, P=0.02) but leucine oxidation did not change significantly in any treatment 
group. Mid thigh muscle mass and VO2max increased (P<0.04) with GHT only.  Expression of muscle 
function genes did not change significantly but the within group comparisons revealed a significant 
increase of androgen receptor expression in the GHT group (P=0.001).  
 
Conclusion: This study showed that 6 months treatment with low dose GH alone or with T in healthy 
elderly men produces comparable increments in whole body protein turnover and protein synthesis. 
 
250 words 
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Introduction 
 
Sarcopenia, an involuntary loss of muscle mass and strength, is a well recognised feature of normal 
ageing. The mechanism for this is probably multifactorial but may be due in part to age-related hormonal 
changes (1).  
 
Normal aging in men is marked by decreases in both GH and testosterone (T) secretion. The 24 h GH 
production rate decreases by approximately 14 % per decade of adult life after puberty (2).  Serum T 
levels begin to decline in the late 3rd decade and then decrease progressively throughout adult life (3). 
Both GH and T are strong anabolic agents, which promote nitrogen retention and increase lean body 
mass (LBM) and protein metabolism in growth hormone deficient (GHD) and hypogonadal men 
respectively (4, 5).  It has been suggested that the changes in body composition in older subjects may be 
related to the age related decrease in GH and T.  
 
In healthy elderly men the rate of muscle protein synthesis and myosin heavy-chain synthesis has been 
shown to correlate positively with IGF-I and T levels (6, 7). In elderly women, GH administration of 0.025 
mg rhGH/kg/d for 1 month was shown to increase whole body protein synthesis and breakdown and to 
increase muscle protein synthesis (8). In healthy elderly men however GH administration for 3 months 
increased muscle mass and strength but failed to affect whole body protein metabolism or muscle protein 
synthesis (9). Near-physiological T treatment for 6 months has been shown to increase LBM and strength 
and reduce muscle protein breakdown in older men (10) whereas low dose testosterone treatment for two 
years in elderly men with low testosterone has shown no beneficial effect on muscle mass and strength  
suggesting a dose-dependent effect (11).  Both GH and T elicit their effect on protein synthesis by binding 
to their receptors and increasing muscle gene transcription, including that of IGF-I (10,12). There is some 
evidence that intramuscular IGF-I rather that of the systemic circulation is of major importance for the 
anabolic action of GH (13). There may therefore be a synergistic effect between the anabolic action of GH 
and T as the administration of T in elderly men increased skeletal muscle IGF-I mRNA and up regulated 
androgen receptor (10).  
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We have investigated the effect of near physiological growth hormone GH and/or T on whole body protein 
turnover in healthy elderly men with relatively low circulating IGF-I and T levels.  Low-dose GH 
replacement was tailored individually the aim being to reverse some of the aging-associated changes 
without significant adverse effects. In order to investigate a possible effect of treatment on skeletal muscle 
gene expression, biopsies were taken from the vastus lateralis.  
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Subjects and Methods 
Participants 
Twenty-four community dwelling elderly men (65 -75 years old) who were healthy and independent, were 
randomised to receive either (i) placebo GH and placebo T (Pl), (ii) recombinant human GH (rhGH) and 
placebo T (GH), (iii) T and placebo rhGH (T) or (iv) rhGH and T (GHT) for six months in a double-blind 
trial. Hospital pharmacists not otherwise involved in the study, randomised participants into treatments 
using computer-generated pre-allocated study numbers. These subjects were a subgroup of a larger 
study of 80 subjects. The effect of the different hormone treatments on LBM, fat body mass (FBM), mid-
thigh muscle cross-sectional area (CSA), muscle strength , aerobic capacity (VO2max),and quality of life 
has been published previously (14). Exclusion criteria were: Any clinically significant disease, body mass 
index (BMI) > 30 kg/m2, evidence of active malignancy, any history of pituitary disease or prostate cancer 
and elevated age-specific levels of prostate specific antigen (PSA) or a palpable prostate nodule. From 
volunteers meeting these criteria whose circulating IGF-I levels were lower than the 50th percentile for the 
local age-specific reference range (145ng/mL), we selected eighty subjects with the lowest testosterone 
levels but excluding those with frank testosterone deficiency (< 173ng/dl: 6.0 nmol/L). The mean 
screening T level of our study participants was 397.6±10ng/dL. Twenty four volunteered to participate in 
the isotope study. The Research Ethics Committee of Guy’s and St Thomas’ Hospitals approved the 
protocol and subjects gave informed written consent. 
 
Study Protocol 
The study was a double blind, randomised and placebo-controlled trial. At baseline  participants gave 
fasting morning blood samples for IGF-I, insulin-like growth factor binding proteins 1 and 3 (IGFBP-1 and 
IGFBP-3), Testosterone, sex hormone binding globulin (SHBG), PSA, glucose, insulin and C-peptide. We 
encountered a problem measuring the insulin levels at the end of the study in two of the subjects in the 
GH group and they were excluded from the analysis.  The same day subjects underwent body 
composition analysis using dual emission x-ray absorptiometry (DEXA; Hologic QDR-4500W scanner, 
Waltham USA) and mid-thigh muscle cross-sectional area (CSA) measurements by computed 
tomography CT (Philips -Tomoscan AV). VO2max was measured using a step-wise maximal exercise test 
on an electromagnetically braked bicycle ergonometer (Lode Excalibur Sport, Groningen, Netherlands) as 
described  (14). Strength was measured in the afternoon of the same day isometrically on handgrip and 
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on the right knee. Right knee (concentric flexion/extension at angular velocities of 60°·sec-1, 90°·sec-1 and 
180°·sec-1) were also performed using a Kin - Com model 125E (Chattecx, Chattanooga,TN). Peak torque 
was calculated using Kin-Com computer software.  
A second appointment was made less than a week from the initial assessment and participants were 
asked to present in the metabolic research area of the Diabetes and Endocrinology Day Center at 
St.Thomas’ Hospital, at 0800 h after an overnight fast. Subjects were instructed not to exercise for 3 days 
prior to this appointment. A priming dose of sodium [13C] bicarbonate (0.2 mg/kg; mass trace) and [1-13C] 
leucine (Tracer Technologies, Somerville, MA, 15 mg/ml, 13C enrichment 99%) was administered followed 
by a constant infusion of [1-13C] leucine (1 mg/kg.h-1) for 9 h.  
Blood samples were obtained 5min before, at baseline and at 180,240,360, 480 and 540min to measure 
the isotopic enrichment and concentration of α -ketoisocaproic acid (KIC). Expired air was collected at the 
same  time points using a GaSampler Breath Collection System (Quintron Instrument Co., Inc., 
Milwaukee, WI,) for the measurement of 13CO2 enrichment. At baseline and at 2, 5 and 8h after the start 
of the infusion the subject’s CO2 production, and oxygen consumption were measured by indirect 
calorimetry (CPX-D, Medical Graphics, Minneapolis,MN).  
At the end of the study a percutaneous muscle biopsy of the vastus lateralis was performed under local 
anaesthesia for the measurement of important skeletal muscle gene expression. The study was repeated 
at 6 months. At visit 1, (week 0 of the treatment period), within two weeks of baseline assessment, 
participants were trained to self-administer their treatment, which commenced that day and continued 
daily for six months.  
 
Dosage and hormone administration 
Testosterone or placebo was given by transdermal patches in a standard dose of 5mg/day. Dosage and 
administration protocol of Human recombinant GH (rhGH) or placebo started at a low fixed dose 
(0.1mg/day) and the dose increased at each study visit until a prearranged target IGF-I levels was 
reached. The rhGH dose was reduced if the IGF-I level was above the 100th percentile of the age specific 
reference range (250ng/mL) and there were likely side-effects or if it was above the 75th percentile of the 
young adult range 380ng/mL. Compliance was monitored by counting the empty vials and used patches 
which had to be returned to our nurse specialist. 
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Analytical methods 
Using gas chromatography-mass spectrometry (5971A MSD, Hewlett-Packard, Palo Alto, CA) and 
selected ion monitoring, αKIC enrichment was measured as the quinoxalinol-trimethylsilyl derivative at 
m/z 232 and 233 (15)  [within-assay coefficient of variation (CV)  <2%]. 13C enrichment of breath CO2 was 
measured on a VG SIRA series II isotope ratio mass spectrometer (VG Isotech, Cheshire, UK; within-
assay CV, <1%).  
Total testosterone was measured on the Bayer ADVIA Centaur analyser by a competitive immunoassay 
using direct chemiluminescent technology. The intra-assay coefficient of variation was 6.2% and the inter-
assay coefficient of variation was 4.4% at 95.5ng/dL, 4.7% and 4.7% at 365.4ng/dL, 2.6%and 4.3% at 
798.3ng/dL and 2.3% and 4.3% at 1009.5ng/dL. The sensitivity and assay range was 10-1500ng/dL 
(0.35-52.1nmol/L).  Free Testosterone (FT) was calculated from the formula: FT (pmol/L) = 6.11-[2.38x 
log (SHBG nmol/L)] x testosterone result x 10. IGFBP-1 and IGFBP-3 were measured using coated tube 
immunoradiometric assay kits, DSL 7800 and DSL 6600 respectively (DSL UK Ltd, Oxon, UK). The intra-
assay CV was 1.8% at 82.7 ng/ml and 3.9% at 7.3 ng/ml. The inter-assay CV was 1.9% at 76.9 ng/ml and 
0.6% at 8.03 ng/ml. The intra-assay CV for IGFBP-1 was 5.2% at 5.2 ng/ml and 2.7% at 144.6 ng/mL. 
The inter-assay CV was 3.5% at 5.16 ng/mL, and 3.6% at 142.03 ng/ml.  Insulin and C peptide were 
measured by double antibody RIA within-assay CV, 6% and 9%, respectively. Glucose was determined 
by an oxygen rate method employing a Beckman Oxygen electrode with within-assay CV of 2%.  
  
 
Calculations 
The kinetics of leucine metabolism were calculated using standard isotope dilution equations for steady 
state conditions. KIC enrichment was used as a measure of intracellular leucine enrichment (16). Leucine 
oxidation rate was calculated from the enrichment of CO2 and the CO2 production rate assuming 80% 
recovery of 13CO2 (17). Rd (rate of disappearance) was assumed to equal Ra, since subjects were 
studied in steady state. The non-oxidative leucine disappearance rate (NOLD; a measure of protein 
synthesis) was calculated as the difference between leucine Rd and leucine oxidation rate. Leucine 
kinetics were expressed as µmol/kg body weight/min. 
 
Muscle biopsy 
 Muscle biopsies were performed at the end of the study. The vastus lateralis was anaesthetised locally 
using lignocaine. A 150mg-tissue sample was removed using a Bergstrom needle and was immediately 
frozen in liquid nitrogen.  
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Muscle mRNA  
A real-time quantitative PCR system (PE Biosystems Prism 7700, Foster City, CA) was used to measure 
the abundance of selected mRNAs in muscle tissue. Transcripts quantified were myosin heavy chain type 
1 (MHC I), MHC IIa, MHC IIx, IGF-I, IGF-II, IGFBP5, PPAR gamma, androgen receptor and GLUT4,and 
the mitochondrial mRNAs cytochrome c oxidase subunit 3 (COX3), and COX4 (18 ) . RNA was extracted 
from skeletal muscle of individual subjects by the Trizol method (Life Technologies, Gaithersburg, MD), 
treated with DNase (Life Technologies) and then reverse-transcribed using the TaqMan Reverse 
Transcription Reagents (PE Biosystems). 
 
Statistical Analyses 
Baseline differences between groups were analysed by one-way analysis of variance, employing the 
Bonferroni correction factor. Changes in outcome measures after 6months of hormone treatment between 
groups were analysed by analysis of covariance (ANCOVA) adjusted for the value of the dependent 
variable at baseline and treatment group. Analysis of covariance was also used for within group 
comparisons.  Linear regression analysis was used to assess relationships between variables. P values < 
0.05 were considered significant. Results are expressed as mean ± SE. Data were analysed using 
StataTM 6.0 computer programme, (Stata Corporation, Texas USA).  
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Results  
 
Subjects characteristics 
 
Three of the twenty four subjects who volunteered to participate in the measurement of leucine kinetics 
did not complete the study. Subjects were well matched in terms of anthropometric and hormonal data. 
Baseline characteristics are shown in Table 1. Subject characteristics, body composition and hormone 
levels in the total study group and this subgroup have been reported previously (14, 17).  
 
Hormone profile (Table 2). 
Testosterone levels increased significantly only in T group (P=0.02), but did not change in GHT group. 
IGF-I levels increased significantly with administration of GH alone (p<0.001) and GHT (p<0.0001) when 
compared to placebo. IGFBP-3 also increased significantly after GHT (p<0.03) and with a trend towards a 
significant increase in the GH group (P=0.07). There were no significant changes in plasma insulin or 
glucose levels in any treatment group. 
 
Whole Body Protein Kinetics (WBPK) (Fig 1, Table 3) 
Leucine Ra and NOLD, increased significantly by 16 + 5.9 % (P=0.015) and by 17.1+ 6.5% (P=0.019) 
after 6m of GH administration respectively. Similarly leucine Ra and NOLD increased significantly by 15.5 
+ 5.9% (P=0.017) and by 16.7+6.5% (P=0.021) respectively in the GHT group. There was no change in 
leucine Ra or NOLD in the T group. Leucine oxidation rate did not change significantly in any treatment 
group compared to placebo. T administration had no effect on leucine Ra or NOLD.  
  
A positive correlation was also found between leucine NOLD and LBM (r=0.47, P<0.0001). At the end of 
the treatment period, changes in IGF-I levels were directly related to changes in leucine Ra (r=0.19, 
P=0.04) and leucine NOLD (r=0.4, P=0.002).     
 
Body composition & middle thigh cross sectional area (CSA) (Table 4) 
Although a trend of increasing LBM was observed after GH (1.4 ± 3.4kg) and after GHT (1.3±3 Kg) this 
did not reach statistical significance (P=0.35) Total fat mass (TFM) decreased by 3.6±5.9 Kg (P=0.015) 
only with GHT. The mid thigh muscle area as assessed by CT scan increased significantly by 7% 
(P=0.05) only after GHT. 
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Aerobic capacity (VO max) & Muscle strength  2
VO max increased significantly (P=0.038) compared to placebo only after GHT administration (table 4). 
No significant changes were recorded in any treatment group in either isokinetic or isometric strength 
measurements (data not shown). 
2
 
Muscle gene transcript levels (Table 5) 
There were no changes in skeletal muscle gene expression for MHC I, MHC IIa, MHC IIx, IGF-I, IGF-II, 
IGFBP5, PPAR gamma, and GLUT4, or the mitochondrial mRNAs COX3 and COX4. The only significant 
change was in androgen receptor levels (AR), which increased significantly after GHT in a within group 
comparison (P=0.04). 
 
 
Adverse events 
 
Mild joint stiffness and muscular pain attributed to GH administration and skin irritation and nipple 
tenderness attributed to T administration, were observed with the same frequency as reported previously 
(14). 
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Discussion  
 
The current study demonstrated that near physiological dose co-administration of GH and T and of GH 
alone for 6 months in healthy elderly men, increased both leucine appearance rate from protein 
breakdown and non-oxidative leucine disposal, a measure of protein synthesis.  These results represent 
the first demonstration of GH and T on an important physiological measurement affecting body protein 
store. 
 
There is controversy as to whether whole body protein synthesis (WBPS) rate declines with ageing (6, 
19). In one report older adults, WBPS expressed in terms of body weight was lower than in young adults 
when however, the data were normalised to LBM no difference was found (20). A recent study in 78 
subjects across the adult age span demonstrated that the rates of WB protein turnover and protein 
synthesis declined with ageing with no age-effect on amino acid oxidation, even after adjustment for LBM 
(21). The differences between these studies may reflect study conditions and methodologies used.  
 
Administration of GH to GHD patients for 1- 8 weeks has been shown to result in a greater increase in 
whole body protein synthesis than proteolysis due to an inhibition of leucine oxidation resulting in an 
improvement in protein balance (4, 22, 23).  This improvement in protein balance can account for the 
increase in LBM reported with GH treatment (4, 24). Similarly in young healthy subjects a high dose of 
GH (67 μg.kg-1.day-1 for 4 weeks) increased protein synthesis and protein breakdown with a decrease in 
leucine oxidation and improvement in protein balance (25). In elderly men GH treatment for 16 weeks 
combined with resistance exercise increased WBPK with no effect in oxidation (26).  The finding in the 
current study of increased protein synthesis and proteolysis with no effect on oxidation with GH treatment 
suggests a new steady state has been reached with an increase in protein turnover. In the short term GH 
would be expected to have a greater effect on protein synthesis than on proteolysis resulting in an 
increase in LBM. The subjects in this study were a subgroup of a larger study of 80 subjects.  Although 
the increase in LBM with GH alone or GH and T was not significant in the subgroup, in the total group a 
significant increase in LBM was found (14). A reduction in both protein turnover and synthesis in elderly 
people represents a reduced capacity to remodel tissues (20). The current study shows that GH 
enhances the remodeling process in older people.  
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In our study physiological doses of T administered transcutaneously failed to produce any significant 
changes in protein turnover. Testosterone administration at a high unphysiologic dose (bi-weekly 
injections of 3mg/kg) for six months has been shown to increase whole body protein synthesis and 
degradation as well as muscle protein synthesis with no effect on leucine oxidation in hypogonadal men 
(5).  In addition intramuscular administration of T for six months at a higher dose than used in this study 
has been shown to increase skeletal muscle protein synthesis in elderly men (10). Failure of T to produce 
any significant changes in our study is most likely due to administration of T via a patch, which results in a 
lower steady (and more physiological) T concentration than weekly (or bi-weekly) intramuscular injections 
that increases peak T  to supraphysiological levels (10). Huang et al (27) also reported, no changes in 
whole body protein turnover in a study where T was administered intramuscularly at a much lower dose 
(100mg/2w) for a six month period in elderly men.   
 
Mauras et. al have shown that co-administration of GH and T to prepubertal GHD boys, markedly 
increases whole body protein synthesis more than when each compound was given separately (28). GH 
and T are thought to elicit an anabolic effect on skeletal muscle by binding to their respective receptors 
and increasing muscle gene transcription including that of IGF-I (29). The synergistic effect of GH and T 
on muscle protein synthesis reported by Mauras et al (28) suggests that GH may augment the effect of T 
on mRNA levels of IGF-I and vice versa (30). In the current study combined GH and T had a similar effect 
as GH alone on protein kinetics, although middle thigh (CSA) muscle mass increased significantly only 
after GH and T. GH and T regulate protein synthesis through different signalling pathways and it is to be 
anticipated that their effects would be additive, if not synergistic. 
 
No changes were found in our study in IGF-I, IGFBP-5 and AR mRNA levels when compared to placebo. 
The only significant change was a within group increase of AR after GHT administration.  
Muscle protein synthesis has been shown to increase by the first week after administration of GH or T 
and this effect to peak by one month. It has been shown that GH and T contribute to muscle protein 
accretion by activating muscle satellite cells possible by increasing intramuscular mRNA of IGF-I (30, 31). 
Thus it is reasonable to hypothesize that the increment of muscle mRNA of IGF-I would occur early after 
the administration of GH or T. Indeed administration of high doses of T intramuscularly in healthy elderly 
men was found to increase expression of AR at one month but not at six months (10). Of note co 
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administration of GH and T, the latter in the form of transdermal patch has been shown to increase 
muscle mRNA of IGF-I after one month of treatment (32). Thus the timing of biopsy in the current study 
may well be explain the failure to demonstrate an increase in muscle AR and IGF-I mRNA despite an 
increase in middle thigh CSA. 
 
An inherent limitation of human studies involving muscle biopsies, is the small numbers prepared to 
undergo the procedure. In the T group only six subjects and in GH, PL and GHT group only five subjects 
underwent muscle biopsies. Thus it is possible that small changes in muscle gene transcript levels 
evaluated in the current study, persisting even at six months after hormone treatment, could have been 
missed due to type II error. 
 
 
In the present study, combined GH and T administration resulted in a significant increase of protein 
synthesis and proteolysis with no effect on leucine oxidation. To our knowledge the combined effect of 
GH (0.025mg.kg-1 3 times/w) and T (100mg/2w im) on WBPK has been investigated by only one previous 
study, which reported similar findings (27) apart from the fact that lower and less frequent GH dosage 
alone had no significant effect. These differences  may also be methodological, as in  the study of Huang 
et al (27), protein kinetics were measured using plasma leucine enrichment which overestimates the 
intracellular leucine enrichment and may lead to errors in the measurement of leucine kinetics. In the 
current study αKIC enrichment was used which provides a more robust measure of intracellular leucine 
enrichment. Daily GH may also be more effective than 3 injections a week. 
 
It has been suggested that the increase in proteolysis observed after GH administration may be due to 
the effect of GH to increase insulin resistance as insulin has been shown to inhibit proteolysis (33). In our 
study the increase in protein degradation, observed after GH and GHT was not associated with increased 
insulin or C-peptide levels. Thus increased insulin resistance seems an unlikely explanation for this. 
 
There were no changes in muscle strength in any of the treatment groups in our study in accordance with 
previous similar studies (34, 35). Myosin heavy chain protein is critical for muscle contractile functions 
and has shown to decline with ageing (6). The same investigators also reported an age-related lowering 
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of the transcript levels of MHCIIa and MHCIIx but not of MHCI mRNA levels and most importantly this 
could not be reversed by 3m of resistance exercise (36). GH and T treatment had no effect on any MHC 
isoform gene expression in our study.   
 
Maximal aerobic capacity (VO max)2  increased in the GHT group only.  A decline in VO max2  with ageing 
has been shown in both cross sectional and longitudinal studies and has been attributed mainly to the 
decline of muscle mass (37). The latter however, could not entirely explain the decline in VO max2  
observed in the elderly as this decline persist even after VO2 max is normalised to muscle mass (38). 
Aerobic performance capacity is determined from functional integrity in respiration, circulation and muscle 
oxidative capacity. Reduced muscle oxidative capacity has been implicated in the decline of VO max2  
observed in the elderly. Indeed   the rates of mitochondrial protein synthesis also decrease with ageing 
and this in turn has been associated with a decline in the expression of cytochrome-c oxidase, subunit II 
and III  (COX-3) and (COX-4) a flux-generating enzyme with a key role in the electron transfer chain in 
muscle fibres  (38,39). Despite a significant increase in VO2max in our study in the GHT group, no 
changes were observed in the mitochondria COX-3 and COX-4 gene expression at 6 months. There are 
two possible interpretations of this observation. Firstly, as we performed biopsies at a single time point 6 
months after hormone treatment, transient changes of mRNA COX-3 and COX-4 would not be detected. 
In addition, a central action of GH and T by increasing cardiac performance could not be excluded (40, 
41).  
 
There is mounting evidence which suggests that GH exerts its anabolic effect mainly by locally produced 
IGF-I rather than a liver-derived circulating IGF-I (13). Of major importance is the identification of a unique 
local IGF-I isoform, known as mechanogrowth factor (MGF), which is specifically expressed in response 
only to changes in the loading state of skeletal muscles (13,30).  The importance of exercise on muscle 
strength can be further substantiated from observations that administration of T or GH could not prevent 
the decline of muscle strength after prolonged bed rest (42). Exercise also increases AR expression and 
the generalised IGF-I isoform in muscle (13, 30) both of which are further upregulated by the increased 
levels of GH secreted in response to exercise in normal young adults (43).  The above findings support 
the role of exercise and hormonal integrity in muscle strength and protein metabolism and may explain 
the failure of GH or T to increase muscle strength in short tem interventional studies. We might expect 
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that through the co-administration of GH and T it is possible to increase exercise capacity, which in turn 
improves (or sustains) physical performance thus preventing the decline of muscle mass and strength.  
 
In conclusion administration of GH alone and GHT in healthy elderly, increased whole body protein 
turnover and the latter had the additional benefit of increasing maximum oxygen uptake and thus muscle 
aerobic performance capacity. Most likely the beneficial effects of exercise would be made more robust 
by replacing the anabolic hormonal milieu, which is deficient in elderly. Trials looking at the effect of 
hormone administration on specific muscle (myofibrillar, mitochondrial) proteins and more importantly 
longer-term trials with the power to define surrogate endpoints of frailty such as falls or dependency are 
urgently needed. 
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Figure legends 
 
Figure 1. Effects of hormone administration on whole body protein kinetics in healthy older men; *,  
P = 0.02. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 23
 
 
 
 
 
 
 
 
 
Table 1. Baseline characteristics of the subjects 
 Placebo 
(n=5) 
GH 
(n=5) 
T 
(n=6) 
GHT 
(n=5) 
All 
(n=21) 
P 
value 
 
Aged(y) 
 
69.8(1.5) 
 
70.6(1.3) 
 
70.3(0.9) 
 
70.4(1.8) 
 
70.2(0.6) 
 
0.98 
 
Weight (Kg) 
 
77.2 ( 5.6) 
 
78.3 (4.3) 
 
77.2 ( 3.8) 
 
83.9 ( 5.3) 
 
80(2.3) 
 
0.68 
 
Body Mass Index (kg/m2) 
 
24.8(1) 
 
26.3(1.3) 
 
26.1(0.9) 
 
27.5(1.6) 
 
26.1(0.5) 
 
0.54 
 
Waist to Hip Ratio 
 
0.95(0.01) 
 
0.95(0.01) 
 
0.9(0.01) 
 
0.94(0.02) 
 
0.93(0.009) 
 
0.16 
 
IGF-I ( ng/mL) 
 
103.8(6.9) 
 
104.5(12.9) 
 
118.3(12.9) 
 
109.1(11.4) 
 
109.1(5.3) 
 
0.80 
 
Testosterone (ng/dL) 
 
507.2(80.6) 
 
440.9(63.4) 
 
495.6(63.4) 
 
512.9(83.5) 
 
489.9(33.4) 
 
0.88 
 
Free T Index  
 
0.22(0.04) 
 
0.14(0.01) 
 
0.18(0.03) 
 
0.14(0.02) 
 
0.17(0.01) 
 
0.18 
 
Free Testosterone pg/mL 
 
121(18) 
 
110(16.4) 
 
121(14.6) 
 
125(22.1) 
 
119(8.3) 
 
0.94 
 
All values are presented as mean (SEM)  
The P value is for the overall comparison between groups. 
To convert testosterone to nmol/L, multiply values by 0.0347.  
To convert IGF-I to nmol/L multiply by 0.131. 
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Table 2. Effects of treatment on T, IGF-I, insulin-like growth factor-binding protein-3 (IGFBP-3), 
insulin-like growth factor-binding protein-1 (IGFBP-1), Insulin, C-peptide and glucose before and 
after 6 months of treatment 
 
 Placebo 
(n=5) 
GH 
(n=5) 
T 
(n=6) 
GHT 
(n=5) 
Testosterone(ng/dL) 
Baseline 
 
507.2(80) 
 
440.9(63) 
 
495.6(63) 
 
512.9(83) 
26 weeks 524.4(69) 536(92) 855.9(181) 665.5(156) 
Change 17(106) 95(112) 357.3(175) 150.1(160) 
P value compared to placebo  0.92 0.028 0.95 
IGF-I (ng/mL) 
baseline 
 
103.8(6.9) 
 
104.5(12) 
 
118.3(12) 
 
109.1(11) 
26 weeks 85.4((6) 179(16) 105((9) 194(25) 
Change -17.5(9) 74(21) -12.9(16) 85.4(27) 
P value compared to placebo  0.001 0.5 <0.0001 
IGFBP-3 (ng/mL) 
Baseline 
 
2993(438) 
 
3498(246) 
 
3571(333) 
 
3254(384) 
26 weeks 2625(331) 3526(187) 3210(309) 3495(383) 
Change -368(550) +27(309) -360(455) +241(543) 
P value compared to placebo  0.07 0.52 0.02 
IGFBP-1(ng/mL) 
Baseline 
 
26.4(8.8) 
 
16.2(4.1) 
 
23.9(4.7) 
 
18.6(8.5) 
26 weeks 24.2(7) 22.8(6.4) 31.5(8.7) 13.13.1) 
Change -2.14(11.3) +6.6(7.6) +7.5(9.9) -5.4(9.1) 
P value compared to placebo  0.62 0.31 0.45 
Insulin (pmol/L) 
Baseline 
 
54.2(7.8) 
 
52.4(3.5) 
 
30.7(13.4) 
 
62.2(13.8) 
26 weeks 47.7(7.5) 68(14.9) 42.1(5.8) 52.2(7.7) 
Change -6.7(10.8) +15.5(6) +11.3(14.6) -9.58(15.8) 
P value compared to placebo  0.08 0.88 0.97 
     
C-Peptide (pmol/L) 
Baseline 
 
1215(139) 
 
879(144) 
 
1270(186) 
 
1270(186) 
26 weeks 492(86) 511(65) 700(62) 699(62) 
Change -722(164) -368(568) -570(196) -570(196) 
P value compared to placebo  0.64 0.34 0.16 
Glucose (mmol/L.) 
Baseline 
 
5.8(0.5) 
 
4.9(0.2) 
 
4.8(0.2) 
 
5.1(0.1) 
26 weeks 5(5) 5.3(0.3) 4.8(0.3) 5.8(0.2) 
Change -0.8(0.6) +0.37(0.4) +0.03(0.3) +0.7(0.3) 
P value compared to placebo  0.54 0.64 0.08 
n = number of participants who completed 6 months  
All values are presented as mean (SE)  
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Table 3 Whole body protein kinetics per Kg body weight (μmol/min/ Kg BW) 
 
 
(μmol/min/ Kg BW) 
Placebo 
(n=5) 
GH 
(n=5) 
T 
(n=6) 
GHT 
(n=5) 
Leucine Ra 
Baseline 
 
1.73(0.1) 
 
1.69(0.04) 
 
1.63(0.02) 
 
1.56(0.06) 
26 weeks 1.6(0.03) 1.85(0.09) 1.56(0.03) 1.71(0.09) 
Change -1.67(0.06) +0.16(0.1) -0.07(0.04) +0.14(0.1) 
P value compared to placebo  0.01 0.99 0.09 
Leucine oxidation rate 
Baseline 
 
0.43(0.07) 
 
0.41(0.05) 
 
0.35(0.04) 
 
0.37(0.02) 
26 weeks 0.41(0.02) 0.46(0.07) 0.32(0.02) 0.42(0.05) 
Change -0.01(0.08) +0.05(0.09) -0.03(0.04) +0.05(0.05) 
P value compared to placebo  0.21 0.25 0.56 
Leucine NOLD  
Baseline 
 
1.3(0.06) 
 
1.28(0.05) 
 
1.27(0.05) 
 
1.18(0.05) 
26 weeks 1.19(0.03) 1.38(0.05) 1.23(0.03) 1.28(0.05) 
Change -0.1(0.07) +0.1(0.07) -0.03(0.06) +0.9(0.07) 
P value compared to placebo  0.003 0.29 0.05 
 
n = number of participants who completed 6 months  
All values are presented as mean (SE)  
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Table 4 Lean body mass, total fat mass and maximal oxygen capacity before and after 
treatment 
 
 Placebo 
(n=5) 
GH 
(n=5) 
T 
(n=6) 
GHT 
(n=5) 
LBM  (kg) 
Baseline 
 
53.2(2.8) 
 
55.7(2) 
 
53.8(1.9) 
 
58(2.1) 
26 weeks 53.2(2.9) 57.2(2.7) 54.4(2.3) 59.3(2) 
Change 0.0 +1.4(3.4) +0.6(3) +1.3(3) 
P value compared to placebo  0.37 0.64 0.52 
Total body fat (kg) 
Baseline 
 
20.8(2.7) 
 
19.4(2.3) 
 
20.1(2) 
 
22.2(4) 
26 weeks 20.4(2.7) 18.2(1.4) 19.4(1.8) 18.6(4.3) 
Change -0.3(3.9) -1.1(2.7) -0.6(2.7) -3.6(5.9) 
P value compared to placebo  0.46 0.81 0.01 
VO2max (ml/kg/min) 
Baseline 
 
23.5(4) 
 
26.1(1.3) 
 
24.6(1.2) 
 
23.1(1.5) 
26 weeks 25.6(4) 28.1(2.4) 26(1.2) 29.4(2.5) 
Change +2(6) +1.9(2) +1.4(1.7) +6.3(3) 
P value compared to placebo  0.97 0.81 0.03 
 
n = number of participants who completed 6 months  
All values are presented as mean (SE)  
 
 
 
 
 
 
 
 
 
 Table 5 Effects of treatment on skeletal muscle gene expression (MyHC-1, MyHC-2a, MyHC-2x 
COX-3, COX-4, AR, IGF-I, IGF-II, IGFBP5, GLUT-4 and PPARa). 
 
 Placebo 
(n=5) 
GH 
(n=5) 
T 
(n=6) 
GHT 
 
 
(n=5)  
Myosin Heavy Chain type 1 
Baseline 
 
0.59(0.1) 
 
0.33(0.08) 
 
0.5(0.1) 
  0.39(0.1) 
 26 weeks 0.52(0.2) 0.34(0.1) 0.44(0.1) 0.57(0.2) 
P value compared to placebo  0.49 0.74 0.94  
Myosin Heavy Chain type 2a 
Baseline 
 
0.33(0.1) 
 
0.29(0.05) 
 
0.45(0.06) 
 
 0.28(0.09) 
26 weeks 0.29(0.1) 0.36(0.1) 0.33(0.1) 0.45(0.1)  
P value compared to placebo  0.64 0.88 0.31 
 
Myosin Heavy Chain  type 2x 
Baseline 
 
0.09 (0.03) 
 
0.33(0.08) 
 
0.18(0.05) 
 
 0.2(0.1) 
26 weeks 0.12 (0.07) 0.18(0.05) 0.2(0.1) 0.32(0.16)  
P value compared to placebo  0.71 0.86 0.47 
 Cytochrome C oxidase 3(COX-3) 
Baseline 
 
0.54(0.5) 
 
0.04(0.01) 
 
0.03(0.01) 
 
0.12(0.1)  
26 weeks 0.02(0.01) 0.03(0.01) 0.05(0.03) 0.19(0.1)  P value compared to placebo  0.85 0.66 0.12 
 27
 Cytochrome C oxidase 4(COX-4) 
Baseline 
 
0.65(0.1) 
 
0.49(0.1) 
 
0.78(0.1) 
 
0.33(0.08)  
26 weeks 0.61(0.1) 0.43(0.1) 0.44(0.1) 0.66(0.2) 
 P value compared to placebo  0.54 0.48 0.79 
IGF-I 
Baseline 
 
0.62(0.1) 
 
0.41(0.1) 
 
0.49(0.06) 
  
0.49(0.2)  26 weeks 0.45(0.1) 0.38(0.07) 0.37(0.1) 0.44(0.1) 
P value compared to placebo  0.9 0.77 0.88  
IGF-II  
Baseline 
 
0.48(0.1) 
 
0.5(0.1) 
 
0.84(0.1) 
  
0.47(0.1) 
 26 weeks 0.59(0.1) 0.51(0.1) 0.46(0.2) 0.55(0.2) 
P value compared to placebo  0.72 0.28 0.88  
IGFBP5  
Baseline 
 
1.1(0.2) 
 
1(0.1) 
 
1.5(0.1) 
  0.9(0.1) 
26 weeks 0.9(0.1) 1.2(0.1) 0.9(0.2) 1.1(0.2)  
P value compared to placebo  0.38 0.93 0.4  
Androgen receptor (AR) 
Baseline 
 
0.81(0.1) 
 
0.70.09) 
 
1.0(0.06) 
 
 0.6(0.1) 
1.1 (0.1) * 26 weeks 0.82(0.2) 0.8(0.2) 0.7(0.1)  
P value compared to placebo  0.71 0.54 0.25  
Peroxisome proliferator-activated 
receptor alpha  (PPARa) 
 
Baseline 
 
 
1.1(0.1) 
 
 
 
1(0.3) 
 
 
 
1.8(0.5) 
 
 
 
 
 
0.9(0.5)  
26 weeks 1.2(0.5) 1.2(0.2) 1(0.3) 0.9(0.1) 
 P value compared to placebo  0.96 0.32 0.35 
GLUT-4 
Baseline 
 
 
0.73(0.1) 
 
 
0.7(0.1) 
 
 
1.0 (0.1) 
 
 
 
 0.6(0.1) 
 26 weeks 0.78(0.1) 0.88(0.1 0.8(0.2) 0.76(0.2) 
P value compared to placebo  0.38 0.93 0.4  
* p=0.04 compared to baseline. 
